Boston Scientific Pays Settlement to States over Surgical Mesh Devices
Posted on 03/23/2021
Boston Scientific Corporation capitulated and agree to pay around US$ 188.6 million in a move to settle claims by most U.S. states that it misled consumers about the safety and effectiveness of its surgical mesh devices. The settlement is with 47 states and Washington, D.C.
“While Boston Scientific was putting income before the health of people in need of care, women were put in danger,” New York Attorney General Letitia James said in a statement.
“Thousands of women suffered intractable pain, incontinence or other problems because they were unaware of the health complications of transvaginal mesh,” said Attorney General Frosh. “Boston Scientific had a duty to tell them about the significant risks and did not. As a result of this settlement, Boston Scientific is required to disclose important risk information to patients and doctors.”
Transvaginal surgical mesh is a synthetic, polypropylene fabric that is implanted in the pelvic floor through the vagina to treat common health conditions in women.
Johnson & Johnson and Becton Dickinson and Co’s CR Bard unit reached multistate settlements over their mesh devices.
